newsfilter
← Latest News
Business Wire·

Personalis and Collaborators to Highlight Ultrasensitive ctDNA Data and New Therapy Resistance Tracking Capabilities at AACR 2026

Oral podium presentation to highlight NeXT Personal® in colorectal cancer; Personalis to debut first data for Real-Time Variant Tracker™ to monitor therapy resistance during NeXT Personal MRD